1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Bronchiolitis Obliterans – Pipeline Review, H1 2013

Bronchiolitis Obliterans – Pipeline Review, H1 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 39 pages

Bronchiolitis Obliterans – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Bronchiolitis Obliterans - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bronchiolitis Obliterans, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiolitis Obliterans. Bronchiolitis Obliterans - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bronchiolitis Obliterans.
- A review of the Bronchiolitis Obliterans products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bronchiolitis Obliterans pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bronchiolitis Obliterans.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bronchiolitis Obliterans pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bronchiolitis Obliterans - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bronchiolitis Obliterans Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bronchiolitis Obliterans 7
Bronchiolitis Obliterans Therapeutics under Development by Companies 9
Bronchiolitis Obliterans Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Bronchiolitis Obliterans Therapeutics - Products under Development by Companies 14
Bronchiolitis Obliterans Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Bronchiolitis Obliterans Therapeutics Development 16
PARI Pharma GmbH 16
APT Pharmaceuticals, Inc. 17
Pacific Therapeutics Ltd. 18
Bronchiolitis Obliterans - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Combination Products 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
cyclosporine - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
(pentoxifylline + N-acetylcysteine) - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
bortezomib - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
cyclosporine - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
interferon gamma-1b - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Bronchiolitis Obliterans Therapeutics - Drug Profile Updates 32
Bronchiolitis Obliterans Therapeutics - Dormant Products 34
Bronchiolitis Obliterans - Product Development Milestones 35
Featured News and Press Releases 35
Nov 13, 2012: Pacific Therapeutics Announces Positive Results From Phase I Trial Of PTL-202 35
Aug 22, 2012: Pacific Therapeutics Completes Enrollment In Clinical Trial Of PTL-202 35
Aug 22, 2012: Pacific Therapeutics Initiates Clinical Trial Of PTL-202 35
Feb 11, 2010: PARI Pharma Enrolls First Patient In Phase IIb Study Of L-CsA 36
Jun 02, 2009: PARI Pharma Reports Successful Phase Ib Clinical Results For Inhaled Liposomal Cyclosporine A And Gains FDA Orphan Drug Designation For The Prevention And Treatment Of Bronchiolitis Obliterans 36
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39



List of Tables

Number of Products Under Development for Bronchiolitis Obliterans, H1 2013 7
Products under Development for Bronchiolitis Obliterans - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
PARI Pharma GmbH, H1 2013 16
APT Pharmaceuticals, Inc., H1 2013 17
Pacific Therapeutics Ltd., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Combination Products, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 24
Bronchiolitis Obliterans Therapeutics - Drug Profile Updates 32
Bronchiolitis Obliterans Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Bronchiolitis Obliterans, H1 2013 7
Products under Development for Bronchiolitis Obliterans - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 19
Assessment by Combination Products, H1 2013 20
Assessment by Route of Administration, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 22
Assessment by Molecule Type, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2016’, ...


ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.